Russell Investments Group Ltd. Has $5.04 Million Holdings in Lantheus Holdings, Inc. $LNTH

Key Points

• Russell Investments Group Ltd. increased its stake in Lantheus Holdings by 204.8% during the 1st quarter, owning a total of 51,682 shares valued at approximately $5 million.
• Lantheus reported a missed EPS estimate of $1.57 for the last quarter, compared to the consensus estimate of $1.65, and its quarterly revenue declined 4.1% year-over-year.
• The stock has a current average rating of "Moderate Buy" from analysts, with an average target price of $105.50, despite several firms lowering their estimates.

Russell Investments Group Ltd. raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 204.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 51,682 shares of the medical equipment provider's stock after purchasing an additional 34,727 shares during the period. Russell Investments Group Ltd. owned 0.08% of Lantheus worth $5,044,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its stake in Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after purchasing an additional 2,610,118 shares during the period. Farallon Capital Management LLC boosted its stake in Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the period. Westfield Capital Management Co. LP boosted its stake in Lantheus by 2.2% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider's stock valued at $155,101,000 after purchasing an additional 34,052 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after purchasing an additional 435,445 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Lantheus by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock valued at $120,510,000 after purchasing an additional 30,891 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of NASDAQ LNTH traded up $0.52 during midday trading on Wednesday, reaching $56.18. The company's stock had a trading volume of 74,436 shares, compared to its average volume of 1,202,845. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average price of $70.60 and a 200 day moving average price of $83.77. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $118.21. The company has a market cap of $3.82 billion, a price-to-earnings ratio of 14.94 and a beta of 0.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The business had revenue of $378.05 million during the quarter, compared to the consensus estimate of $389.69 million. During the same quarter in the previous year, the firm earned $1.80 earnings per share. The firm's revenue for the quarter was down 4.1% compared to the same quarter last year. On average, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director directly owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,838,066 shares of company stock worth $384,430,031 in the last ninety days. 2.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. B. Riley reduced their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Mizuho reduced their price target on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. JMP Securities reduced their price target on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. Truist Financial set a $63.00 price target on shares of Lantheus and gave the stock a "hold" rating in a research note on Monday, August 11th. Finally, William Blair reaffirmed a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $105.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.